Imatinib, a tyrosine kinase inhibitor of the oncogenic BCR-ABL protein expressed by chronic myelogenous leukaemia (CML) cells, shows off-target effects, including on Lck expressed in T cells. This evidence concerns the gene ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive.